APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars Insulin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biosimilars Insulin Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchBiosimilars Insulin Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Insulin Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Biosimilars Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Insulin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Insulin Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Biosimilars Insulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biosimilars Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilars Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biosimilars Insulin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biosimilars Insulin market include Tonghua Dongbao, Sanofi, United Laboratories, Eli Lilly, Gan & Lee Pharmaceuticals, Boehringer Ingelheim and Biocon/Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biosimilars Insulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilars Insulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilars Insulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilars Insulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilars Insulin Segment by Company

Tonghua Dongbao

Sanofi

United Laboratories

Eli Lilly

Gan & Lee Pharmaceuticals

Boehringer Ingelheim

Biocon/Mylan

Biosimilars Insulin Segment by Type

Insulin Aspart

Insulin Lispro

Insulin Glargine

Other

Biosimilars Insulin Segment by Application

Type I Diabetes

Type II Diabetes

Biosimilars Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biosimilars Insulin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biosimilars Insulin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biosimilars Insulin significant trends, drivers, influence factors in global and regions.

6. To analyze Biosimilars Insulin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilars Insulin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilars Insulin industry.

Chapter 3: Detailed analysis of Biosimilars Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biosimilars Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biosimilars Insulin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biosimilars Insulin Industry Trends Table 2. Biosimilars Insulin Industry Drivers Table 3. Biosimilars Insulin Industry Opportunities and Challenges Table 4. Biosimilars Insulin Industry Restraints Table 5. Global Biosimilars Insulin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biosimilars Insulin Revenue Share by Company (2021-2026) Table 7. Global Biosimilars Insulin Sales Volume by Company (k units) & (2021-2026) Table 8. Global Biosimilars Insulin Sales Volume Share by Company (2021-2026) Table 9. Global Biosimilars Insulin Average Price (US$/unit) of Company (2021-2026) Table 10. Global Biosimilars Insulin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biosimilars Insulin Key Company Manufacturing Base & Headquarters Table 12. Global Biosimilars Insulin Company, Product Type & Application Table 13. Global Biosimilars Insulin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilars Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Insulin Aspart Table 18. Significant Companies of Insulin Lispro Table 19. Significant Companies of Insulin Glargine Table 20. Significant Companies of Other Table 21. Global Biosimilars Insulin Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Biosimilars Insulin Sales Volume by Type (2021-2026) & (k units) Table 23. Global Biosimilars Insulin Sales Volume by Type (2027-2032) & (k units) Table 24. Global Biosimilars Insulin Sales Volume Share by Type (2021-2026) Table 25. Global Biosimilars Insulin Sales Volume Share by Type (2027-2032) Table 26. Global Biosimilars Insulin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biosimilars Insulin Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Biosimilars Insulin Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Biosimilars Insulin Sales Value Share by Type (2021-2026) Table 30. Global Biosimilars Insulin Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Type I Diabetes Table 32. Significant Companies of Type II Diabetes Table 33. Global Biosimilars Insulin Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Biosimilars Insulin Sales Volume by Application (2021-2026) & (k units) Table 35. Global Biosimilars Insulin Sales Volume by Application (2027-2032) & (k units) Table 36. Global Biosimilars Insulin Sales Volume Share by Application (2021-2026) Table 37. Global Biosimilars Insulin Sales Volume Share by Application (2027-2032) Table 38. Global Biosimilars Insulin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Biosimilars Insulin Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Biosimilars Insulin Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Biosimilars Insulin Sales Value Share by Application (2021-2026) Table 42. Global Biosimilars Insulin Sales Value Share by Application (2027-2032) Table 43. Global Biosimilars Insulin Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Biosimilars Insulin Sales by Region (2021-2026) & (k units) Table 45. Global Biosimilars Insulin Sales Market Share by Region (2021-2026) Table 46. Global Biosimilars Insulin Sales by Region (2027-2032) & (k units) Table 47. Global Biosimilars Insulin Sales Market Share by Region (2027-2032) Table 48. Global Biosimilars Insulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Biosimilars Insulin Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Biosimilars Insulin Sales Value Share by Region (2021-2026) Table 51. Global Biosimilars Insulin Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Biosimilars Insulin Sales Value Share by Region (2027-2032) Table 53. Global Biosimilars Insulin Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Biosimilars Insulin Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Biosimilars Insulin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Biosimilars Insulin Sales by Country (2021-2026) & (k units) Table 58. Global Biosimilars Insulin Sales Market Share by Country (2021-2026) Table 59. Global Biosimilars Insulin Sales by Country (2027-2032) & (k units) Table 60. Global Biosimilars Insulin Sales Market Share by Country (2027-2032) Table 61. Global Biosimilars Insulin Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Biosimilars Insulin Sales Value Market Share by Country (2021-2026) Table 63. Global Biosimilars Insulin Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Biosimilars Insulin Sales Value Market Share by Country (2027-2032) Table 65. Tonghua Dongbao Company Information Table 66. Tonghua Dongbao Business Overview Table 67. Tonghua Dongbao Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Tonghua Dongbao Biosimilars Insulin Product Portfolio Table 69. Tonghua Dongbao Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Sanofi Biosimilars Insulin Product Portfolio Table 74. Sanofi Recent Development Table 75. United Laboratories Company Information Table 76. United Laboratories Business Overview Table 77. United Laboratories Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. United Laboratories Biosimilars Insulin Product Portfolio Table 79. United Laboratories Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Eli Lilly Biosimilars Insulin Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Gan & Lee Pharmaceuticals Company Information Table 86. Gan & Lee Pharmaceuticals Business Overview Table 87. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolio Table 89. Gan & Lee Pharmaceuticals Recent Development Table 90. Boehringer Ingelheim Company Information Table 91. Boehringer Ingelheim Business Overview Table 92. Boehringer Ingelheim Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Boehringer Ingelheim Biosimilars Insulin Product Portfolio Table 94. Boehringer Ingelheim Recent Development Table 95. Biocon/Mylan Company Information Table 96. Biocon/Mylan Business Overview Table 97. Biocon/Mylan Biosimilars Insulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Biocon/Mylan Biosimilars Insulin Product Portfolio Table 99. Biocon/Mylan Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Biosimilars Insulin Distributors List Table 103. Biosimilars Insulin Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Biosimilars Insulin Product Image Figure 2. Global Biosimilars Insulin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Insulin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biosimilars Insulin Sales (2021-2032) & (k units) Figure 5. Global Biosimilars Insulin Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Biosimilars Insulin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Insulin Aspart Image Figure 10. Insulin Lispro Image Figure 11. Insulin Glargine Image Figure 12. Other Image Figure 13. Global Biosimilars Insulin Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Biosimilars Insulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Biosimilars Insulin Sales Volume Share by Type (2021-2032) Figure 16. Global Biosimilars Insulin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Biosimilars Insulin Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Biosimilars Insulin Sales Value Share by Type (2021-2032) Figure 19. Type I Diabetes Image Figure 20. Type II Diabetes Image Figure 21. Global Biosimilars Insulin Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Biosimilars Insulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Biosimilars Insulin Sales Volume Share by Application (2021-2032) Figure 24. Global Biosimilars Insulin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Biosimilars Insulin Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Biosimilars Insulin Sales Value Share by Application (2021-2032) Figure 27. Global Biosimilars Insulin Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Biosimilars Insulin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Biosimilars Insulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Biosimilars Insulin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Biosimilars Insulin Sales Value (2021-2032) & (US$ Million) Figure 32. North America Biosimilars Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Biosimilars Insulin Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Biosimilars Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Biosimilars Insulin Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Biosimilars Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Biosimilars Insulin Sales Value (2021-2032) & (US$ Million) Figure 38. South America Biosimilars Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Biosimilars Insulin Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Biosimilars Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Biosimilars Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Biosimilars Insulin Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Biosimilars Insulin Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Aspart
  • Insulin Lispro
  • Insulin Glargine
  • Other
Applications
  • Type I Diabetes
  • Type II Diabetes
Companies covered
  • Tonghua Dongbao
  • Sanofi
  • United Laboratories
  • Eli Lilly
  • Gan & Lee Pharmaceuticals
  • Boehringer Ingelheim
  • Biocon/Mylan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilars Insulin Sales Value (2021-2032)
  4. 1.2.2 Global Biosimilars Insulin Sales Volume (2021-2032)
  5. 1.2.3 Global Biosimilars Insulin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biosimilars Insulin Market Dynamics
  1. 2.1 Biosimilars Insulin Industry Trends
  2. 2.2 Biosimilars Insulin Industry Drivers
  3. 2.3 Biosimilars Insulin Industry Opportunities and Challenges
  4. 2.4 Biosimilars Insulin Industry Restraints
3 Biosimilars Insulin Market by Company
  1. 3.1 Global Biosimilars Insulin Company Revenue Ranking in 2025
  2. 3.2 Global Biosimilars Insulin Revenue by Company (2021-2026)
  3. 3.3 Global Biosimilars Insulin Sales Volume by Company (2021-2026)
  4. 3.4 Global Biosimilars Insulin Average Price by Company (2021-2026)
  5. 3.5 Global Biosimilars Insulin Company Ranking (2024-2026)
  6. 3.6 Global Biosimilars Insulin Company Manufacturing Base and Headquarters
  7. 3.7 Global Biosimilars Insulin Company Product Type and Application
  8. 3.8 Global Biosimilars Insulin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biosimilars Insulin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biosimilars Insulin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biosimilars Insulin Market by Type
  1. 4.1 Biosimilars Insulin Type Introduction
  2. 4.1.1 Insulin Aspart
  3. 4.1.2 Insulin Lispro
  4. 4.1.3 Insulin Glargine
  5. 4.1.4 Other
  6. 4.2 Global Biosimilars Insulin Sales Volume by Type
  7. 4.2.1 Global Biosimilars Insulin Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Biosimilars Insulin Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Biosimilars Insulin Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Biosimilars Insulin Sales Value by Type
  11. 4.3.1 Global Biosimilars Insulin Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Biosimilars Insulin Sales Value by Type (2021-2032)
  13. 4.3.3 Global Biosimilars Insulin Sales Value Share by Type (2021-2032)
5 Biosimilars Insulin Market by Application
  1. 5.1 Biosimilars Insulin Application Introduction
  2. 5.1.1 Type I Diabetes
  3. 5.1.2 Type II Diabetes
  4. 5.2 Global Biosimilars Insulin Sales Volume by Application
  5. 5.2.1 Global Biosimilars Insulin Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Biosimilars Insulin Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Biosimilars Insulin Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Biosimilars Insulin Sales Value by Application
  9. 5.3.1 Global Biosimilars Insulin Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Biosimilars Insulin Sales Value by Application (2021-2032)
  11. 5.3.3 Global Biosimilars Insulin Sales Value Share by Application (2021-2032)
6 Biosimilars Insulin Regional Sales and Value Analysis
  1. 6.1 Global Biosimilars Insulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilars Insulin Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilars Insulin Sales by Region: 2021-2026
  4. 6.2.2 Global Biosimilars Insulin Sales by Region (2027-2032)
  5. 6.3 Global Biosimilars Insulin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biosimilars Insulin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biosimilars Insulin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biosimilars Insulin Sales Value by Region (2027-2032)
  9. 6.5 Global Biosimilars Insulin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biosimilars Insulin Sales Value (2021-2032)
  12. 6.6.2 North America Biosimilars Insulin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biosimilars Insulin Sales Value (2021-2032)
  15. 6.7.2 Europe Biosimilars Insulin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biosimilars Insulin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biosimilars Insulin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biosimilars Insulin Sales Value (2021-2032)
  21. 6.9.2 South America Biosimilars Insulin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biosimilars Insulin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biosimilars Insulin Sales Value Share by Country, 2025 VS 2032
7 Biosimilars Insulin Country-level Sales and Value Analysis
  1. 7.1 Global Biosimilars Insulin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biosimilars Insulin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biosimilars Insulin Sales by Country (2021-2032)
  4. 7.3.1 Global Biosimilars Insulin Sales by Country (2021-2026)
  5. 7.3.2 Global Biosimilars Insulin Sales by Country (2027-2032)
  6. 7.4 Global Biosimilars Insulin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biosimilars Insulin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biosimilars Insulin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biosimilars Insulin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biosimilars Insulin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biosimilars Insulin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao
  2. 8.1.1 Tonghua Dongbao Company Information
  3. 8.1.2 Tonghua Dongbao Business Overview
  4. 8.1.3 Tonghua Dongbao Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao Biosimilars Insulin Product Portfolio
  6. 8.1.5 Tonghua Dongbao Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Biosimilars Insulin Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 United Laboratories
  14. 8.3.1 United Laboratories Company Information
  15. 8.3.2 United Laboratories Business Overview
  16. 8.3.3 United Laboratories Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 United Laboratories Biosimilars Insulin Product Portfolio
  18. 8.3.5 United Laboratories Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Biosimilars Insulin Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Gan & Lee Pharmaceuticals
  26. 8.5.1 Gan & Lee Pharmaceuticals Company Information
  27. 8.5.2 Gan & Lee Pharmaceuticals Business Overview
  28. 8.5.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolio
  30. 8.5.5 Gan & Lee Pharmaceuticals Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Biosimilars Insulin Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
  37. 8.7 Biocon/Mylan
  38. 8.7.1 Biocon/Mylan Company Information
  39. 8.7.2 Biocon/Mylan Business Overview
  40. 8.7.3 Biocon/Mylan Biosimilars Insulin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biocon/Mylan Biosimilars Insulin Product Portfolio
  42. 8.7.5 Biocon/Mylan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilars Insulin Value Chain Analysis
  2. 9.1.1 Biosimilars Insulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilars Insulin Sales Mode & Process
  6. 9.2 Biosimilars Insulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilars Insulin Distributors
  9. 9.2.3 Biosimilars Insulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst